Condition
High Grade Fallopian Tube Serous Adenocarcinoma
Total Trials
4
Recruiting
0
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
0
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (2)
P 2 (1)
Trial Status
Active Not Recruiting2
Terminated1
Withdrawn1
Clinical Trials (4)
Showing 4 of 4 trials
NCT03943173Early Phase 1Active Not Recruiting
Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery
NCT05114421Phase 2Active Not RecruitingPrimary
Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients
NCT02756130Phase 1WithdrawnPrimary
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)
NCT03924245Phase 1Terminated
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
Showing all 4 trials